3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Active not recruiting
7
Completed
3
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
TIC10 compound
3
trastuzumab deruxtecan
2
umbralisib
1
ublituximab
1
pembrolizumab
1
infigratinib
1
enfortumab vedotin
1
duvelisib
1
blinatumomab
1
belumosudil
1
Rituximab
1
KD025
1
Gemcitabine
1
Crizotinib
1
Cisplatin
1
Carboplatin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Has announcements
×
trastuzumab deruxtecan
×
Clear all
NCT03248492
2025-06-26
DESTINY-Breast01
Daiichi Sankyo
Phase 2
Terminated
253 enrolled
21 charts
1 FDA
NCT03505710
2025-05-30
DESTINY-Lung01
Daiichi Sankyo
Phase 2
Terminated
181 enrolled
17 charts
1 FDA